Nuevolution to present new data on its BET BD1 program supporting the understanding of the biological mode-of-action
Stockholm, 27 October 2017. Nuevolution AB (publ) (NUE.ST) today announced that Søren Jensby Nielsen, Director of Biology, will be presenting new data on Nuevolution’s selective bromodomain BET BD1 inhibitor at the 5th Annual Meeting of the Cytokine and Interferon Society, held 29 October - 2 November in Kagasawa, Japan. At the conference, new data on Nuevolution’s selective bromodomain BET BD1 inhibitor, NUE7770, will be presented. This includes gene expression profiles showing selective and potent inhibition of a small and select set of immune-related genes. These data support the